Home › Research › Digital health tools
The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family
Spina S, Farlow MR, Unverzagt FW, Kareken DA, Murrell JR, Fraser G, Epperson F, Crowther RA et al.. Brain : a journal of neurology, 2007-12-07
Topic: Brain proteins, microglia and lab models
Plain-language summary
Multiple system tauopathy with presenile dementia (MSTD) is an inherited disease caused by a (g) to (a) transition at position +3 in intron 10 of Tau. It belongs to the spectrum of frontotemporal dementia and parkinsonism linked to chromosome 17 with mutations in Tau (FTDP-17T). Here we present the longitudinal clinical, neuropsychological, neuroimaging, neuropathological, biochemical and genetic characterization of the MSTD family. Presenting signs were consistent with the behavioural variant of frontotemporal dementia in 17 of 21 patients. Two individuals presented with an atypical form of progressive supranuclear palsy and two others with either severe postural imbalance or an isolated short-term memory deficit. Memory impairment was present at the onset in 15 patients, with word finding difficulties and stereotyped speech also being common. Parkinsonism was first noted 3 years after the onset of symptoms. Neuroimaging showed the most extensive grey matter loss in the hippocampus, parahippocampal gyrus and frontal operculum/insular cortex of the right hemisphere and, to a lesser extent, in the anterior cingulate gyrus, head of the caudate nucleus and the posterolateral orbitofrontal cortex and insular cortex bilaterally. Neuropathologically, progressive nerve cell loss, gliosis and coexistent neuronal and/or glial deposits consisting mostly of 4-repeat tau were present in frontal, cingulate, temporal and insular cortices, white matter, hippocampus, parahippocampus, basal ganglia, selected brainstem nuclei and spinal cord. Tau haplotyping indicated that specific haplotypes of the wild-type allele may act as modifiers of disease presentation. Quantitative neuroimaging has been used to analyse the progression of atrophy in affected individuals and for predicting disease onset in an asymptomatic mutation carrier. This multidisciplinary study provides a comprehensive description of the natural history of disease in one of the largest known families with FTDP-17T.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 21 participants. Brain scans showed the most shrinkage in memory and insular regions on the right side, and brain tissue showed deposits made mostly of "4-repeat" tau. This is a rare inherited frontotemporal dementia, not Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Spina, S., Farlow, M. R., Unverzagt, F. W., Kareken, D. A., Murrell, JR., Fraser, G., et al. (2008). The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain : a journal of neurology. https://doi.org/10.1093/brain/awm280
Vancouver
Spina S, Farlow MR, Unverzagt FW, Kareken DA, Murrell JR, Fraser G, et al. The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family. Brain : a journal of neurology. 2008. doi:10.1093/brain/awm280. PMID: 18065436.
BibTeX
@article{spina2008-18065436,
author = {Spina, S. and Farlow, M. R. and Unverzagt, F. W. and Kareken, D. A. and Murrell, JR. and Fraser, G. and Epperson, F. and Crowther, R. A. and others},
title = {{The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family}},
journal = {Brain : a journal of neurology},
year = {2008},
doi = {10.1093/brain/awm280},
pmid = {18065436},
url = {https://doi.org/10.1093/brain/awm280}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Tau haplotyping indicated that specific haplotypes of the wild-type allele may act as modifiers of disease presentation.
Why it matters
In one family carrying an inherited Tau mutation (a change at position +3 in intron 10), most of the 21 patients (17) first showed behavioural changes typical of frontotemporal dementia, memory problems were present at onset in 15, and movement problems (parkinsonism) appeared about 3 years after symptoms began. Brain scans showed the most shrinkage in memory and insular regions on the right side, and brain tissue showed deposits made mostly of "4-repeat" tau. This is a rare inherited frontotemporal dementia, not Alzheimer's disease. The study tests no treatment, and its suggestion that variation in the normal copy of the Tau gene "may" shape symptoms is unconfirmed.
New to this subject? Start with our plain-English guide: Digital health →
Study details
- Study designlongitudinal study
- Participants21
- Evidence strengthModerate
How this study scored 62/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Brain : a journal of neurology) |
| Journal's citation record | 4 / 4 | Brain: journal h-index 503 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 21 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 102 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.1 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 1 / 6 | Cited 0.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 12 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Bernardino Francesco Ghetti: h-index 121 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Cambridge: institution h-index 1,973 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18065436) |
| Free to read | 2 / 2 | Free to read |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
12 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Digital health tools from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.